HLS Therapeutics Inc. is a specialty pharmaceutical company focused on acquiring and commercializing products in the central nervous system and cardiovascular markets in Canada. The company boasts a strong gross margin of 81.8% and a solid EBITDA margin of 35.4%, indicating effective cost management. However, concerns arise from a negative net margin of -22.4% and declining returns on equity and assets, suggesting profitability challenges. While high margins are promising, the low market cap of $127.76M raises questions about overall valuation and growth potential.
Loading financial metrics...
Company posted a loss of $-12.4M over the last year, representing 22.4% of revenue.
Debt of $51.5M is 4.4x the company's cash position of $11.7M.
Operating margin expanded by 12.8pp, demonstrating strong operational leverage.
Exceptional gross margin of 81.8% indicates strong pricing power and competitive moat.
Operating cash flow surged 114.0% YoY, indicating strong cash generation capability.
Excellent operating cash flow margin of 30.9% indicates high-quality earnings.
Free cash flow increased 114.0% YoY, enhancing capital allocation optionality.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2025-FY (December 31, 2025)